Valisure applauds Congresswoman Rosa DeLauro (CT-03) for her leadership in championing drug safety reformthrough the Recall Unsafe Drugs Act—a critical step toward empowering the U.S. Food and Drug Administration (FDA) with the authority to mandate recalls of harmful drug and homeopathic products.

Historically, the FDA has had mandatory recall authority over products like medical devices, food, and biologics, but not prescription or over-the-counter drugs. This gap forced the agency to rely on voluntary action from manufacturers, even in cases where evidence showed that products posed serious health risks.

On February 16, 2017, Congresswoman DeLauro introduced the Recall Unsafe Drugs Act to close this dangerous loophole. She reintroduced the bill again on January 10, 2020, during a press conference that called for the ban of ranitidine—the active ingredient in Zantac—after Valisure identified high levels of NDMA, a probable human carcinogen, in ranitidine products.

Joining Congresswoman DeLauro at the press conference were:

• David Light, Co-Founder & President of Valisure
• Joe Graedon, Pharmacologist and Co-Host of The People’s Pharmacy on NPR
• Dr. Jon Ernstoff, Gastroenterologist at MidState Medical Center

Following years of persistent advocacy, a major milestone was achieved on February 4, 2022, when provisions from the Recall Unsafe Drugs Act were included in the America COMPETES Act of 2022, which passed the House that same morning. The bill represents a landmark shift in how the FDA can respond to dangerous pharmaceutical products.

Congresswoman DeLauro’s work continues to resonate across the healthcare community, and Valisure is proud to support efforts that bring greater transparency, accountability, and safety to the U.S. drug supply.

Valisure applauds Congresswoman Rosa DeLauro (CT-03) for her leadership in championing drug safety reformthrough the Recall Unsafe Drugs Act—a critical step toward empowering the U.S. Food and Drug Administration (FDA) with the authority to mandate recalls of harmful drug and homeopathic products.

Historically, the FDA has had mandatory recall authority over products like medical devices, food, and biologics, but not prescription or over-the-counter drugs. This gap forced the agency to rely on voluntary action from manufacturers, even in cases where evidence showed that products posed serious health risks.

On February 16, 2017, Congresswoman DeLauro introduced the Recall Unsafe Drugs Act to close this dangerous loophole. She reintroduced the bill again on January 10, 2020, during a press conference that called for the ban of ranitidine—the active ingredient in Zantac—after Valisure identified high levels of NDMA, a probable human carcinogen, in ranitidine products.

Joining Congresswoman DeLauro at the press conference were:

• David Light, Co-Founder & President of Valisure
• Joe Graedon, Pharmacologist and Co-Host of The People’s Pharmacy on NPR
• Dr. Jon Ernstoff, Gastroenterologist at MidState Medical Center

Following years of persistent advocacy, a major milestone was achieved on February 4, 2022, when provisions from the Recall Unsafe Drugs Act were included in the America COMPETES Act of 2022, which passed the House that same morning. The bill represents a landmark shift in how the FDA can respond to dangerous pharmaceutical products.

Congresswoman DeLauro’s work continues to resonate across the healthcare community, and Valisure is proud to support efforts that bring greater transparency, accountability, and safety to the U.S. drug supply.